Can corticosteroids be beaten in future asthma therapy?

Pharmazie

Volumn 61, Issue 2, 2006, Pages 122-124

  Amon, A ^a   Pahl, A ^a   Szelenyi, Istvan ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; CORTICOSTEROID; CYCLIC AMP; ETIPREDNOL DICLOACETATE; HISTAMINE H1 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LOTEPREDNOL ETABONATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHODIESTERASE IV; PROTEIN SERINE THREONINE KINASE; STRESS ACTIVATED PROTEIN KINASE;

ALLERGIC RHINITIS; ANGIONEUROTIC EDEMA; ARTICLE; ASTHMA; COMBINATORIAL CHEMISTRY; DRUG DESIGN; HUMAN; MORBIDITY; MORTALITY; SCREENING TEST; URTICARIA;

ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; INFLAMMATION MEDIATORS;

EID: 33644510189     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Baeumer W, Szelenyi I, Kietzmann M (2005) Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD. Expert Rev Clin Immunol 1: 27-36.
2. Bodor N (1995) Retrometabolic approaches to drug targeting. NIDA Res Monogr 154: 1-27.
3. Bodor N (2001) Retrometabolic drug design-novel aspects, future directions. Pharmazie 56 (Suppl 1): S67-74.
4. Busse WW, Middleton E, Storms W, Dockhom RJ, Chu TJ, Grossman J, Weiler JM, Bronsky EA, Mansfield LE, Bell TD, Hemsworth GR, Perhach JL, D'Eletto TA, Dam A (1996) Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Am J Respir Crit Care Med 153: 122-127.
5. Chialda L, Zhang M, Brune K, Pahl A (2005) Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia. Respir Res 15: 36-55.
6. Honda K, Marquillies P, Capron M, Dombrowicz D (2004) Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol 113: 882-888.
7. Ichinose M, Barnes PJ (2004) Cytokine-directed therapy in asthma. Curr Drug Targets Inflamm Allergy 3: 263-269.
8. Kurucz I, Toth S, Nemeth K, Torok K, Csillik-Perczel V, Pataki A, Salamon C, Nagy Z, Szekely JI, Horvath K, Bodor N (2003) Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166). J Pharmacol Exp Ther 307: 83-92.
9. Larsen JS (2001) Do antihistamines have a role in asthma therapy? Pharmacotherapy 21: 28S-33S.
10. Maziak W, Behrens T, Brasky TM, Duhme H, Rzehak P, Weiland SK, Keil U (2003) Are asthma and allergies in children and adolescents increasing? Results from ISAAC phase I and phase III surveys in Münster, Germany. Allergy 58: 572-579.
11. Szelenyi I, Hochhaus G, Heer S, Kusters S, Marx D, Poppe H, Engel J (2000) Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc) 36: 313-320.